Andrew Stewart Plump insider trades: Takeda Pharmaceutical (TAK) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Andrew reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | TAK | ↓ Sell | 116,191 | $18.49 | $2.1M | By Trust | Sep 3, 2026 (1d) |
| Aug 19, 2026 | TAK | ↓ Sell | 19,651 | $18.49 | $363K | By Trust | Aug 21, 2026 (2d) |
| Aug 10, 2026 | TAK | ↓ Sell | 165,393 | $17.10 | $2.8M | Direct | Aug 12, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TAK insiders
Open-market trades in the last 12 months
About Andrew Stewart Plump's insider trades
Andrew Stewart Plump is President, R&D at Takeda Pharmaceutical (TAK). Since Aug 10, 2026, Andrew has reported no open-market purchases and 3 sales worth $5.3M on SEC Form 4. In the last 12 months: 3 sales ($5.3M).
Their filings also include grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TAK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.